Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Constellation Healthcare Technologies Inc's plan pays off

Constellation Healthcare Technologies’ buy and build strategy certainly appears to be working.
Doctor using a tablet device
The group has more than 9,000 doctors on its books.

Constellation Healthcare Technologies’ (LON:CHT) buy and build strategy certainly appears to be working, judging by the annual results statement.

Revenues rose 40% to US$76.7mln in the 12 months ended last December, giving growth in underlying profits (EBITDA) of US$16.1mln, uo 115%.

Conversion of those profits into cash was good as money it made from operations rose 91% to US$15.5mln.

The layering on of new businesses masked a strong underlying growth rate of 8.8%.

Constellation describes itself as an RCM, or a revenue cycle management company. Essentially, what it does for more than 9,000 doctors on its books is bill and collect monies owed by government, insurers and patients.

It also provides practice management and purchasing services.

Consolidation play 

Obamacare, or the Affordable Care Act to give it its proper name, has created huge upheaval for physicians, complicating the rules on payment while forcing down remuneration.

For the barely profitable small firms carrying out mission-critical billing operations, Obamacare adds a financially onerous level of bureaucracy that is often the final straw.

For Constellation, it has whipped up the perfect storm – or at the very least a great backdrop - against which to consolidate a highly fragmented market.

In December the company unveiled its fourth deal of a fairly short life as a stock market-quoted company when it paid US$30mln for MDRX Medical Billing.

Talking about full-year results, chief executive Paul Parmar said: "Constellation enjoyed a successful year across all metrics.

“We increased our revenue base and more importantly, significantly increased our profitability for the year.

“Our acquisition and integration strategy is proven and we are quickly becoming one of the largest healthcare and technology services businesses in the US.”

finnCap’s punchy price target

The broker reckons the stock is worth 310p more than double the closing share price.

It points out the business is trading on a forward multiple of less than 10 times earnings 8%-plus free cash flow.

Ian_55ae0ddd437b7.jpg


Register here to be notified of future CHT Company articles
View full CHT profile

Constellation Healthcare Technologies, Inc. Timeline

Related Articles

FatCity.jpg
January 13 2016
If everyone could be as active as the York-based outfit there would not be such a pressing demand for its products.
shutterstock_184785974.jpg
April 28 2016
Last year's acquisition of Kinesis Pharma meant that it could now offer a one-stop shop for its pharmaceuticals clients and expand its client base.
1-Operation.jpg
April 12 2016
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.